FDA Adverse Event Injury Summary report: N

ASR RESURFACING HEAD

MDR report key: 2210460 · Received August 9, 2011

Report

Report Number
1818910-2011-15131
Event Type
Injury
Date Received
August 9, 2011
Report Date
July 22, 2011
Manufacturer
DEPUY INTERNATIONAL, LTD.
Product Code
KXA
PMA / PMN Number
NA
Removal / Correction Number
Z1749/1816-2011
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
AS
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

THE ASR PLATFORM WAS VOLUNTARILY RECALLED FROM THE MARKET IN AUGUST 2010, AND THE ASR PRODUCT CODES ARE NOW CONSIDERED INACTIVE. FURTHER INVESTIGATION OF THIS INDIVIDUAL INCIDENT WILL NOT BE UNDERTAKEN, AS THERE IS AN ONGOING INVESTIGATION REGARDING THE ROOT CAUSE(S) AND/OR CORRECTIVE ACTIONS. (B)(4).

Additional Manufacturer Narrative · 1

THE ASR PLATFORM WAS VOLUNTARILY RECALLED FROM THE MARKET IN (B)(6) 2010, AND THE ASR PRODUCT CODES ARE NOW CONSIDERED INACTIVE. FURTHER INVESTIGATION OF THIS INDIVIDUAL INCIDENT WILL NOT BE UNDERTAKEN, AS THERE IS AN ONGOING INVESTIGATION REGARDING THE ROOT CAUSE(S) AND/OR CORRECTIVE ACTIONS. REF. (B)(4). DEPUY CONSIDERS THE INVESTIGATION CLOSED AT THIS TIME. SHOULD THE PRODUCT AND/OR ADDITIONAL INFORMATION BE RECEIVED, THE INVESTIGATION WILL BE RE-OPENED.

Description of Event or Problem · 1

MALE PATIENT - (B)(6) OLD WAS PRESENTED WITH A DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL). PATIENT HAD BILATERAL ASR HIPS IMPLANTED SIX YEARS AGO ASR RESURFACING AND AN ASR XL WITH CORAIL STEM. SURGEON'S INITIAL ASSESSMENT IS THAT FROM THE POSITION OF THE ASR RESURFACING HEAD ON THE X-RAY IT APPEARS THAT THERE HAS BEEN EDGE LOADING AND SUBSEQUENT WEAR. CHROMIUM AND COBALT BLOOD LEVELS ARE 800 AND 1300 MMOL/L RESPECTIVELY. CAUSALITY ASSESSMENT BY SURGEON/ONCOLOGIST IS THAT THE CLL IS POSSIBLY RELATED TO THE HIGH CHROMIUM AND COBALT LEVELS.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 ASR RESURFACING HEAD TOTAL HIP PROSTHESIS KXA DEPUY INTERNATIONAL, LTD. NA UNKNOWN

Patients

Seq Age Sex Outcome Treatment
1 58 YR Required Intervention